Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X by Tobias Büttner, Urologist in Advanced Training, adding:
“Post SBRT image evaluation ambiguities are real and certainly an issue. It theoretically might undermines a patient’s outcome if mismanaged (unnecessary biopsies, etc).
Although the theoretical harms associated with that maybe similar in frequency to postop complication rates after nephrectomy. Which is why I think we really need a RCT to confirm the benefit of surgery at this time in history to feel better about endorsing an operation.”
Quoting Tobias Büttner’s post:
“SBRT is excellent for inoperable RCC! But for operable pts, the bar is high: Robotic partial nephrectomy offers good safety and low toxicity.
Plus, SBRT competes with surgery + full histology + adjuvant therapy options.
And yet, no biomarker = tricky post-SBRT imaging?”
Other articles featuring Drew Moghanaki on OncoDaily.